# TOLNAFTATE- tolnaftate cream NuCare Pharmaceuticals, Inc.

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

-----

#### **Drug Facts**

### **Active ingredient**

Tolnaftate USP 1%

### **Purpose**

**Antifungal** 

#### Uses

- for effective treatment of most athlete's foot (tinea pedis), jock itch (tinea cruris) and ringworm (tinea corporis)
- for effective relief of itchy, scaly skin between the toes
- clears up most athlete's foot infection and with daily use helps keep it from coming back

### **Warnings**

### For external use only

#### Do not use

• on children under 2 years of age unless directed by a doctor

When using this product avoid contact with eyes

### Stop use and ask a doctor if

- irritation occurs or if there is no improvement within 4 weeks (for athlete's foot and ringworm)
- irritation occurs or if there is no improvement within 2 weeks (for jock itch)

### Keep this and all drugs out of the reach of children.

In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

#### **Directions**

- clean the affected area and dry thoroughly
- apply a thin layer of the product over the affected area twice daily (morning and

- night) or as directed by a doctor
- supervise children in the use of this product

#### For athlete's foot

- use daily for 4 weeks. If condition persists longer, consult a doctor
- pay special attention to the spaces between the toes
- wear well fitting ventilated shoes
- change shoes and socks at least once daily

For ringworm, use daily for 4 weeks. If condition persists longer, consult a doctor. For jock itch, use daily for 2 weeks. If condition persists longer, consult a doctor. This product is not effective on the scalp or nails.

#### Other information

- Store at controlled room temperature 15°-30°C (59°-86°F)
- Lot No. and Exp date: see crimp on tube or see box

### Inactive ingredients

Ceteth-20, Cetostearyl Alcohol, Chlorocresol, Mineral Oil, Propylene Glycol, Purified Water, Sodium Phosphate Monobasic, White Petrolatum

#### Questions?

Adverse Drug Event call (800)616-2471

Dist. By MAJOR PHARMACEUTICALS, 31778 Enterprise Drive, Livonia, MI 48150 USA Re-Oder No. 100497 M-88 Rev. 9/09 Manufactured in USA

### **Principal Display Panel -**



### **TOLNAFTATE**

tolnaftate cream

#### **Product Information**

Product Type HUMAN OTC DRUG Item Code (Source) NDC:68071-4245(NDC:0904-0722)

**Route of Administration** TOPICAL

### **Active Ingredient/Active Moiety**

| Ingredient Name  | <b>Basis of Strength</b> | Strength     |
|--|--------------------------|--------------|
| TOLNAFTATE (UNII: 06KB629TKV) (TOLNAFTATE - UNII:06KB629TKV) | TOLNAFTATE               | 10 mg in 1 g |

| Inactive Ingredients                                      |          |  |
|---|----------|--|
| Ingredient Name   | Strength |  |
| WATER (UNII: 059QF0KO0R)                                  |          |  |
| CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)                    |          |  |
| CETETH-20 (UNII: 1835H2IHHX)                              |          |  |
| CHLOROCRESOL (UNII: 36W53O7109)                           |          |  |
| MINERAL OIL (UNII: T5L8T28FGP)                            |          |  |
| PETROLATUM (UNII: 4T6H12BN9U)                             |          |  |
| SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS (UNII: KH7I04HPUU) |          |  |
| PROPYLENE GLYCOL (UNII: 6DC90167V3)                       |          |  |

| Packaging |                      |  |                         |                       |
|-----------|----------------------|--|-------------------------|-----------------------|
| #         | Item Code            | Package Description                                  | Marketing Start<br>Date | Marketing End<br>Date |
| 1         | NDC:68071-<br>4245-5 | 14.18 g in 1 TUBE; Type 0: Not a Combination Product | 01/22/2018              |                       |

| <b>Marketing In</b>   | Marketing Information                       |                         |                       |  |
|-----------------------|---|-------------------------|-----------------------|--|
| Marketing<br>Category | Application Number or Monograph<br>Citation | Marketing Start<br>Date | Marketing End<br>Date |  |
| OTC monograph final   | part333C                                    | 02/11/2010              |                       |  |
|                       |   |                         |                       |  |

## Labeler - NuCare Pharmaceuticals,Inc. (010632300)

| Establishment                |         |           |                            |  |
|------------------------------|---------|-----------|----------------------------|--|
| Name                         | Address | ID/FEI    | <b>Business Operations</b> |  |
| NuCare Pharmaceuticals, Inc. |         | 010632300 | relabel(68071-4245)        |  |

Revised: 2/2021 NuCare Pharmaceuticals,Inc.